

INTERNATIONAL ISOTOPES INC  
Form 10KSB/A  
April 30, 2008

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION**

**Washington, D. C. 20549**

**FORM 10-KSB/A**

**Amendment No. 1**

ANNUAL REPORT UNDER SECTION 13 OR 15 (d) OF THE

SECURITIES EXCHANGE ACT OF 1934

For the fiscal year ended December 31, 2007

OR

TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE

SECURITIES EXCHANGE ACT OF 1934

For the transition period from \_\_\_\_\_ to \_\_\_\_\_

Commission file number

000-22923

**INTERNATIONAL ISOTOPES INC.**

*(Exact name of issuer as specified in its charter)*

**Texas**

*(State of incorporation)*

**74-2763837**

*(IRS Employer Identification Number)*

**4137 Commerce Circle**

**Idaho Falls, Idaho**

*(Address of principal executive offices)*

**83401**

*(zip code)*

(208) 524-5300

*(Registrant's telephone number, including area code)*

Securities registered under Section 12(g) of the Exchange Act:

-----  
COMMON STOCK, \$.01 PAR VALUE

*(Title of Class)*

Check whether the issuer is not required to file reports pursuant to Section 13 or 15(d) of the Exchange Act ( )

Check whether the issuer (1) filed all reports required to be filed by Section 13 or 15 (d) of the Exchange Act during the past 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. YES (X) NO ( )

Check if there is no disclosure of delinquent filers in response to Item 405 of Regulation S-B contained in this form, and no disclosure will be contained, to the best of registrant's knowledge, in definitive proxy or information statements incorporated by reference in Part III of this Form 10-KSB or any amendment to this Form 10-KSB.

Indicate by checkmark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).  
YES ( ) NO ( X)

The Issuer's revenue for the fiscal year ended December 31, 2007 was \$4,690,588.

The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to be the average bid and asked price of such common equity at March 5, 2008 was \$92,820,000.

As of April 25, 2008 the number of shares outstanding of common stock, \$.01 par value was 265,665,967 shares.

Transition Small Business Disclosure Format. YES ( ) NO (X)

## EXPLANATORY NOTE

This Form 10-KSB/A constitutes Amendment No. 1 to the Annual Report on Form 10-KSB for the year ended December 31, 2007 (the Form 10-KSB ), filed by the Registrant with the Commission on March 28, 2008. The sole purpose of this amendment is to file with the Commission the information required by Item 12 of Part III of Form 10-KSB that was not included in the Registrant's Proxy Statement filed with the Commission on April 21, 2008 and incorporated by reference to the Form 10-KSB pursuant to General Instruction E(3) to Form 10-KSB. There are no other changes made by this Amendment No. 1.

As required by Rule 12b-15, in connection with this Form 10-KSB/A the Registrant's Chief Executive Officer and Chief Financial Officer are providing Rule 13a-14(a) certifications dated as of April 30, 2008. Except as described above, this Amendment does not modify or update disclosure in, or exhibits to, the Form 10-KSB. Furthermore, this amendment does not change any previously reported financial results, nor does it reflect events occurring after the date of the filing of the Form 10-KSB.

## PART III.

### Item 12. CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS

#### *Securities Authorized for Issuance under Equity Compensation Plans*

We currently maintain three compensation plans that provide for the issuance of our Common Stock to officers and other employees, directors and consultants, the 2002 Long Term Incentive Plan, the International Isotopes Employee Stock Purchase Plan and the 2006 Equity Incentive Plan, each of which have been approved by our shareholders. The following table sets forth information regarding outstanding options and shares reserved for future issuance under the foregoing plans as of December 31, 2007:

#### **Equity Compensation Plan Information December 31, 2007**

<b>Plan Category</b>	<b>(a)</b> <b>Number of securities to be issued upon exercise of outstanding options, warrants, and rights</b>	<b>(b)</b> <b>Weighted-average exercise price of outstanding options, warrants, and rights</b>	<b>(c)</b> <b>Number of securities remaining available for future issuance under equity compensation plans (excluding securities reflected in column) (a)</b>
Equity compensation plans approved by shareholders:	21,950,000	\$ .10	17,082,291(1)
Equity compensation plans not approved by shareholders		\$	
<b>Total</b>	<b>21,950,000</b>	<b>\$ .10</b>	<b>17,082,291</b>

(1) Includes 15,350,000 shares available for issuance under the 2006 Equity Incentive Plan and 1,732,291 shares available for issuance under the International Isotopes Employee Stock Purchase Plan. Up to 16,150,000 shares that are currently subject to outstanding options granted under the 2002 Long Term Incentive Plan may become available for issuance under the Company's 2006 Equity Incentive Plan in the future to the extent those shares are not issued (for example, if those options expire without being exercised). Shares available for issuance under the Company's 2006 Equity Incentive Plan may be granted in the form of stock options, stock awards, restricted stock awards, restricted stock units, stock appreciation rights or any other form of equity compensation approved by the Compensation Committee or the Board

**SIGNATURES**

In accordance with Section 13 or 15(d) of the Exchange Act, the registrant caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

**International Isotopes Inc.**

Date: April 30, 2008

/s/ Steve T. Laflin  
Steve T. Laflin  
President, Chief Executive Officer,  
Secretary, and Director

**EXHIBIT INDEX**

<b>Exhibit Number</b>	<b>Description of Document</b>
31.1	Certification under section 302 of the Sarbanes-Oxley Act of 2002 for Chief Executive Officer.
31.2	Certification under section 302 of the Sarbanes-Oxley Act of 2002 for Chief Financial Officer.